CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on Tuesday, August 12, 2025, at 3:00 PM ET.
Investors and interested parties can access the live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.
CVRx (NASDAQ: CVRX), un'azienda nel settore dei dispositivi medici in fase commerciale specializzata in soluzioni di neuromodulazione per le malattie cardiovascolari, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Il team di gestione dell'azienda terrà una presentazione il martedì 12 agosto 2025, alle 15:00 ET.
Investitori e interessati potranno seguire la presentazione in diretta audio streaming attraverso la sezione relazioni con gli investitori del sito web di CVRx all'indirizzo ir.cvrx.com.
CVRx (NASDAQ: CVRX), una empresa de dispositivos médicos en etapa comercial especializada en soluciones de neuromodulación para enfermedades cardiovasculares, ha anunciado su participación en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. El equipo directivo de la compañía realizará una presentación el martes 12 de agosto de 2025, a las 3:00 PM ET.
Los inversores y las partes interesadas pueden acceder a la transmisión en vivo del audio de la presentación a través de la sección de relaciones con inversores en el sitio web de CVRx en ir.cvrx.com.
CVRx (NASDAQ: CVRX)는 심혈관 질환을 위한 신경조절 솔루션을 전문으로 하는 상업 단계 의료기기 회사로, Canaccord Genuity 제45회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 8월 12일 화요일 오후 3시(동부시간)에 발표를 진행할 예정입니다.
투자자 및 관심 있는 분들은 CVRx 웹사이트의 투자자 관계 섹션 ir.cvrx.com을 통해 발표의 실시간 오디오 웹캐스트를 시청할 수 있습니다.
CVRx (NASDAQ : CVRX), une entreprise de dispositifs médicaux en phase commerciale spécialisée dans les solutions de neuromodulation pour les maladies cardiovasculaires, a annoncé sa participation à la 45e conférence annuelle sur la croissance de Canaccord Genuity. L'équipe de direction de l'entreprise présentera une intervention le mardi 12 août 2025 à 15h00 (heure de l'Est).
Les investisseurs et les parties intéressées peuvent accéder à la diffusion audio en direct de la présentation via la section relations investisseurs du site web de CVRx à l'adresse ir.cvrx.com.
CVRx (NASDAQ: CVRX), ein medizinisches Unternehmen in der kommerziellen Phase, das sich auf Neuromodulationslösungen für Herz-Kreislauf-Erkrankungen spezialisiert hat, hat seine Teilnahme an der 45. jährlichen Wachstums-Konferenz von Canaccord Genuity angekündigt. Das Management-Team des Unternehmens wird am Dienstag, den 12. August 2025, um 15:00 Uhr ET eine Präsentation halten.
Investoren und Interessierte können den Live-Audio-Webcast der Präsentation über den Investor-Relations-Bereich auf der CVRx-Website unter ir.cvrx.com verfolgen.
- None.
- None.
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast.
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
When is CVRx presenting at the Canaccord Genuity Growth Conference?
How can investors access CVRx's presentation at the Canaccord conference?
What does CVRx (NASDAQ: CVRX) specialize in?
Which conference is CVRx participating in during August 2025?
